Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 78

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Tetrac Can Replace Thyroid Hormone During Brain Development in Mouse Mutants Deficient in the Thyroid Hormone Transporter Mct8

Horn, Sigrun, Kersseboom, Simone, Mayerl, Steffen, Müller, Julia, Groba, Claudia, Trajkovic-Arsic, Marija, Ackermann, Tobias, Visser, Theo J., Heuer, Heike·2013·Endocrinology

Abstract

The monocarboxylate transporter 8 (MCT8) plays a critical role in mediating the uptake of thyroid hormones (THs) into the brain. In patients, inactivating mutations in the MCT8 gene are associated with a severe form of psychomotor retardation and abnormal serum TH levels. Here, we evaluate the therapeutic potential of the TH analog 3,5,3′,5′-tetraiodothyroacetic acid (tetrac) as a replacement for T4 in brain development. Using COS1 cells transfected with TH transporter and deiodinase constructs, we could show that tetrac, albeit not being transported by MCT8, can be metabolized to the TH receptor active compound 3,3′,5-triiodothyroacetic acid (triac) by type 2 deiodinase and inactivated by type 3 deiodinase. Triac in turn is capable of replacing T3 in primary murine cerebellar cultures where it potently stimulates Purkinje cell development. In vivo effects of tetrac were assessed in congenital hypothyroid Pax8-knockout (KO) and Mct8/Pax8 double-KO mice as well as in Mct8-KO and wild-type animals after daily injection of tetrac (400 ng/g body weight) during the first postnatal weeks. This treatment was sufficient to promote TH-dependent neuronal differentiation in the cerebellum, cerebral cortex, and striatum but was ineffective in suppressing hypothalamic TRH expression. In contrast, TSH transcript levels in the pituitary were strongly down-regulated in response to tetrac. Based on our findings we propose that tetrac administration offers the opportunity to provide neurons during the postnatal stage with a potent TH receptor agonist, thereby eventually reducing the neurological damage in patients with MCT8 mutations without deteriorating the thyrotoxic situation in peripheral tissues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2012-1628

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 48

  1. Dumitrescu, 2004, A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene, Am J Hum Genet, 74, 168, 10.1086/380999 · DOI · Paper page
  2. Schwartz, 2005, Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene, Am J Hum Genet, 77, 41, 10.1086/431313 · DOI · Paper page
  3. Friesema, 2006, Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8, Nat Clin Pract Endocrinol Metab, 2, 512, 10.1038/ncpendmet0262 · DOI
  4. Refetoff, 2007, Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination, Best Pract Res Clin Endocrinol Metab, 21, 277, 10.1016/j.beem.2007.03.005 · DOI · Paper page
  5. Friesema, 2010, Genetics and phenomics of thyroid hormone transport by MCT8, Mol Cell Endocrinol, 322, 107, 10.1016/j.mce.2010.01.016 · DOI
  6. Oppenheimer, 1997, Molecular basis of thyroid hormone-dependent brain development, Endocr Rev, 18, 462
  7. de Escobar, 2004, Maternal thyroid hormones early in pregnancy and fetal brain development, Best Pract Res Clin Endocrinol Metab, 18, 225, 10.1016/j.beem.2004.03.012 · DOI · Paper page
  8. Bernal, 2005, Thyroid hormones and brain development, Vitam Horm, 71, 95, 10.1016/S0083-6729(05)71004-9 · DOI · Paper page
  9. Wemeau, 2008, Beneficial effects of propylthiouracil plus l-thyroxine treatment in a patient with a mutation in MCT8, J Clin Endocrinol Metab, 93, 2084, 10.1210/jc.2007-2719 · DOI
  10. Wirth, 2009, Neuronal 3′,3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome, J Neurosci, 29, 9439, 10.1523/JNEUROSCI.6055-08.2009 · DOI · Paper page
  11. Sugiyama, 2003, Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine, J Biol Chem, 278, 43489, 10.1074/jbc.M306933200 · DOI · Paper page
  12. Tohyama, 2004, Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier, Endocrinology, 145, 4384, 10.1210/en.2004-0058 · DOI
  13. Ito, 2011, Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys, J Pharm Sci, 100, 3939, 10.1002/jps.22487 · DOI · Paper page
  14. Di Cosmo, 2009, A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport, Endocrinology, 150, 4450, 10.1210/en.2009-0209 · DOI
  15. Nakamura, 1978, An assessment of the concentration of acetic acid and propionic acid derivatives of 3,5,3′-triiodothyronine in human serum, J Clin Endocrinol Metab, 46, 91, 10.1210/jcem-46-1-91 · DOI
  16. Engler, 1984, The deiodination of the iodothyronines and of their derivatives in man, Endocr Rev, 5, 151, 10.1210/edrv-5-2-151 · DOI · Paper page
  17. Wu, 2005, Alternate pathways of thyroid hormone metabolism, Thyroid, 15, 943, 10.1089/thy.2005.15.943 · DOI · Paper page
  18. Green, 1961, The peripheral metabolism of tri- and tetraiodothyroacetic acids in man, J Clin Endocrinol Metab, 21, 1548, 10.1210/jcem-21-12-1548 · DOI
  19. Pitt-Rivers, 1953, Physiological activity of the acetic-acid analogues of some iodinated thyronines, Lancet, 265, 234, 10.1016/S0140-6736(53)90164-0 · doi:10.1016/s0140-6736(53)90164-0
  20. Lerman, 1956, Physiologic activity of triiodo- and tetraiodo-thyroacetic acid in human myxedema, J Clin Endocrinol Metab, 16, 1470, 10.1210/jcem-16-11-1470 · DOI
  21. Lerman, 1961, Dissociation of response to triiodothyroacetic acid in myxedema: comparison with response to thyroid substance, J Clin Endocrinol Metab, 21, 1044, 10.1210/jcem-21-9-1044 · DOI
  22. Kunitake, 1989, 3,5,3′-Triiodothyroacetic acid therapy for thyroid hormone resistance, J Clin Endocrinol Metab, 69, 461, 10.1210/jcem-69-2-461 · DOI
  23. Ueda, 1996, Differences in response of thyrotropin to 3,5,3′-triiodothyronine and 3,5,3′-triiodothyroacetic acid in patients with resistance to thyroid hormone, Thyroid, 6, 563, 10.1089/thy.1996.6.563 · DOI
  24. Radetti, 1997, Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance, Thyroid, 7, 775, 10.1089/thy.1997.7.775 · DOI
  25. Messier, 2000, Triac regulation of transcription is T3 receptor isoform- and response element-specific, Mol Cell Endocrinol, 165, 57, 10.1016/S0303-7207(00)00266-5 · DOI
  26. Menegay, 1989, Pharmacokinetics of 3,5,3′-triiodothyroacetic acid and its effects on serum TSH levels, Acta Endocrinol (Copenh), 121, 651, 10.1530/acta.0.1210651 · DOI
  27. Liang, 1997, Organ-specific effects of 3,5,3′-triiodothyroacetic acid in rats, Eur J Endocrinol, 137, 537, 10.1530/eje.0.1370537 · DOI · Paper page
  28. Mansouri, 1998, Follicular cells of the thyroid gland require Pax8 gene function, Nat Genet, 19, 87, 10.1038/ng0598-87 · DOI · Paper page
  29. Flamant, 2002, Congenital hypothyroid Pax8−/− mutant mice can be rescued by inactivating the TRα gene, Mol Endocrinol, 16, 24
  30. Heuer, 2003, Thyroid hormone induces cerebellar Purkinje cell development via the thyroid hormone receptor α1, J Neurosci, 23, 10604, 10.1523/JNEUROSCI.23-33-10604.2003 · DOI
  31. Friedrichsen, 2003, Regulation of iodothyronine deiodinases in the Pax8−/− mouse model of congenital hypothyroidism, Endocrinology, 144, 777, 10.1210/en.2002-220715 · DOI
  32. Friesema, 2008, Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10, Mol Endocrinol, 22, 1357, 10.1210/me.2007-0112 · DOI · Paper page
  33. Iniguez, 1996, Cell-specific effects of thyroid hormone on RC3/neurogranin expression in rat brain, Endocrinology, 137, 1032, 10.1210/endo.137.3.8603571 · DOI
  34. Gilbert, 2007, Thyroid hormone insufficiency during brain development reduces parvalbumin immunoreactivity and inhibitory function in the hippocampus, Endocrinology, 148, 92, 10.1210/en.2006-0164 · DOI
  35. Namba, 2008, Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter, Eur J Pediatr, 167, 785, 10.1007/s00431-007-0589-6 · DOI
  36. Sijens, 2008, 1H magnetic resonance spectroscopy in monocarboxylate transporter 8 gene deficiency, J Clin Endocrinol Metab, 93, 1854, 10.1210/jc.2007-2441 · DOI
  37. Vaurs-Barriere, 2009, Pelizaeus-Merzbacher-like disease presentation of MCT8 mutated male subjects, Ann Neurol, 65, 114, 10.1002/ana.21579 · DOI
  38. Pacini, 1982, Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization, J Endocrinol Invest, 5, 403, 10.1007/BF03350541 · DOI
  39. Asteria, 1999, Prenatal diagnosis of thyroid hormone resistance, J Clin Endocrinol Metab, 84, 405, 10.1210/jcem.84.2.5479 · DOI
  40. Guran, 2009, 9 years follow-up of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of d-thyroxine and triiodothyroacetic acid (TRIAC), J Pediatr Endocrinol Metab, 22, 971, 10.1515/JPEM.2009.22.10.971 · DOI
  41. Mellström, 1991, Independent expression of the α and ß c-erbA genes in developing rat brain, Mol Endocrinol, 5, 1339, 10.1210/mend-5-9-1339 · DOI · Paper page
  42. Bradley, 1992, Spatial and temporal expression of α- and ß thyroid hormone receptor mRNAs, including the ß2-subtype, in the developing mammalian nervous system, J Neurosci, 12, 2288, 10.1523/JNEUROSCI.12-06-02288.1992 · DOI · Paper page
  43. Wallis, 2010, The thyroid hormone receptor α1 protein is expressed in embryonic postmitotic neurons and persists in most adult neurons, Mol Endocrinol, 24, 1904, 10.1210/me.2010-0175 · DOI
  44. Gereben, 2005, Pretranslational regulation of type 2 deiodinase, Thyroid, 15, 855, 10.1089/thy.2005.15.855 · DOI
  45. Williams, 2011, Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase, J Endocrinol, 209, 261, 10.1530/JOE-10-0448 · DOI · Paper page
  46. Lameloise, 2001, Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy, Eur J Endocrinol, 144, 145, 10.1530/eje.0.1440145 · DOI · Paper page
  47. Hernandez, 2005, Structure and function of the type 3 deiodinase gene, Thyroid, 15, 865, 10.1089/thy.2005.15.865 · DOI
  48. Dupre, 2004, Both thyroid hormone receptor (TR)β1 and TRβ2 isoforms contribute to the regulation of hypothalamic thyrotropin-releasing hormone, Endocrinology, 145, 2337, 10.1210/en.2003-1209 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Horn, S., Kersseboom, S., Mayerl, S., Müller, J., Groba, C., Trajkovic-Arsic, M., Ackermann, T., Visser, T. J., & Heuer, H.
Venue
Endocrinology
Published
2013-01-10
Volume
154
Issue
2
Pages
968-979
ISSN
  • 0013-7227
  • 1945-7170
Cited by
78
References
11
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tetrac Can Replace Thyroid Hormone During Brain Development in Mouse Mutants Deficient in the Thyroid Hormone Transporter Mct8. https://app.cochat.ai/papers/10.1210/en.2012-1628
The paper
Horn, S., Kersseboom, S., Mayerl, S., Müller, J., Groba, C., Trajkovic-Arsic, M., Ackermann, T., Visser, T. J., & Heuer, H. (2013). Tetrac Can Replace Thyroid Hormone During Brain Development in Mouse Mutants Deficient in the Thyroid Hormone Transporter Mct8. Endocrinology. https://doi.org/10.1210/en.2012-1628

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.